SR9009 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-07-10. Numbers and descriptions here follow the published literature rather than marketing material.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
=== GLMA: Health Professionals Advancing LGBTQ Equality === GLMA: Health Professionals Advancing LGBTQ Equality is the world's largest and oldest LGBTQ healthcare professionals association founded in 1981. It is also formerly known as the Gay and Lesbian Medical Association. GLMA provides resources along with educational programs to help healthcare professionals gain the knowledge and skills in giving appropriate care to LGBTQ patients whilst hosting conferences and workshops to foster the environment for discussion of the latest research or emerging issues in the field. They also conduct LGBTQ centered research to identify the disparities and health needs to publish guidelines and inform about evidence-based healthcare practices and policies to LGBTQ health.
== Safety == There hasn't been extensive research conducted on the safety of sandalwood oil. But because there haven't been any significant adverse effects documented in scientific literature, it continues to be used cosmetically and in food. A few studies were found to identify sandalwood oil's potential toxic effects, but it was determined to be safe at the present levels that the oil is used in food as flavorings.
=== Economic solar panel === The MAXXUN project was to develop a system of disruptive solar cells based on the luminescent solar concentrating (LSC) technology, in order to lower the investment for a solar energy system by more than half. Altran Technologies consultants have worked during a year with the award-winning team to increase the surface area of the panel from 2.5 cm2 to 10 cm2; to apply an absorbing and dispersing layer on this extra surface area; to optimize light power under different conditions; to build a demonstration model and to identify potential partners.
Sources: en.wikipedia.org
Monazite geochronology can also reveal igneous differentiation events such as magma mixing, where the magma chamber is evolved into a different composition. Isomorphous substitution is one of the examples. It is a form of substitution in which one element is replaced by another without changing the crystal structure. In the case of monazite, the rare earth elements are replaced by Ca and Th.
All major powers engaged in espionage, using a great variety of spies, double agents, moles, and new technologies such as the tapping of telephone cables. The Soviet KGB ("Committee for State Security"), the bureau responsible for foreign espionage and internal surveillance, was famous for its effectiveness. The most famous Soviet operation involved its atomic spies that delivered crucial information from the United States' Manhattan Project, leading the USSR to detonate its first nuclear weapon in 1949, four years after the American detonation and much sooner than expected. A massive network of informants throughout the Soviet Union was used to monitor dissent from official Soviet politics and morals. Although to an extent disinformation had always existed, the term itself was invented, and the strategy formalized by a black propaganda department of the Soviet KGB. Based on the amount of top-secret Cold War archival information that has been released, historian Raymond L. Garthoff concludes there probably was parity in the quantity and quality of secret information obtained by each side. However, the Soviets probably had an advantage in terms of HUMINT (human intelligence or interpersonal espionage) and "sometimes in its reach into high policy circles." In terms of decisive impact, however, he concludes:
A year later, a further discovery was made at Lindow Moss, just 250 m (820 ft) southwest of the Lindow Woman. On 1 August 1984, Andy Mould, who had been involved in the discovery of Lindow Woman, took what he thought was a piece of wood off the elevator of the peat-shredding machine. He threw the object at Eddie Slack, his workmate. When it hit the ground, peat fell off the object and revealed it to be a human foot. The police were called, and the foot was taken away for examination. At the same time Rachel Pugh, a trainee journalist for The Wilmslow World, was tipped off about the discovery. At the urging of her editor, she cycled out to the site of the discovery and persuaded the two men to show her where the foot had been excavated. Recognising the possible historical significance of the find, she told the diggers to stop work at once, and alerted Rick Turner, the Cheshire County Archaeologist, who subsequently succeeded in finding the rest of the body, which later became known as Lindow Man. Some skin had been exposed and had started to decay, so to prevent further deterioration of the body, it was re-covered with peat. The complete excavation of the block containing the remains was performed on 6 August. Until it could be dated, it was moved to the Macclesfield District General Hospital for storage. As the body of Malika Reyn-Bardt had still not been found, it was initially thought possible the body might be hers, until it was determined to be male, and radiocarbon dated.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.